Wojciech Jurczak, MD, PhD, head of the Department of Oncology at Maria Sklodowska-Curie National Research Institute of Oncology, discusses the changing therapy landscape for relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Wojciech Jurczak, MD, PhD, head of the Department of Oncology at Maria Sklodowska-Curie National Research Institute of Oncology, discussed the changing therapy landscape for relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Transcript
How might the findings of the phase 2 L-MIND study help inform clinical practice and treatment decisions for patients with relapsed or refractory DLBCL?
The perspective of relapsing/refractory diffuse large B-cell lymphoma is changing evidently. We have the dusk of classical chemotherapy as we know, including high-dose chemo, and transplant is gradually replaced by a targeted chemotherapy, molecular targeted agents, and, last but not least, immunotherapy. It is difficult to use molecular targeted agents with the present diagnostic methods—it should be noticed that even at this EHA [European Hematology Association annual meeting], there were some data on CDK9 inhibitors. The targeted chemotherapy is widely used, but what's most important is immunotherapy.
Now, the CAR [chimeric antigen receptor] T cells are approved in the third line and now are being moved to the second line of therapy. The targeted chemotherapy approved in the second line after the POLARIX study is gradually moved to the first line, with immunities like [the] TAFA-LEN [tafasitamab plus lenalidomide] regimen being reserved for the patients who are not eligible for the CAR T-cell therapies either because of age, comorbidities, or logistical problems. As this is a regimen which is excellently tolerated, we can still offer it to the majority of elderly populations, which we do not like to treat with a more harsh Pola-BR regimen, including targeted chemotherapy [polatuzumab vedotin and rituximab] together with bendamustine.
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More